Alopecia, Androgenetic
Conditions
Brief summary
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
Detailed description
Protocol 239-11651-203 is a Phase 2 study entitled A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia Eligible subjects will be randomized (1:1:1) to 1 of the 3 groups (low dose vs high dose vs placebo) and treated for 16 weeks.
Interventions
DRUGTDM-105795, 0.0025%
The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
DRUGTDM-105795, 0.02%
The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
DRUGTDM-105795 topical vehicle solution
The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Sponsors
Therapeutics, Inc.
Technoderma Medicines Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
To enter the study, a subject must meet the following criteria: 1. Subject is male, 18-55 years old. 2. Subject has provided written informed consent. 3. Subject has a clinical diagnosis of mild to moderate androgenetic alopecia (AGA) in temple and vertex region with a score of IIIv, IV, or V on the Modified Norwood-Hamilton Scale. 4. Subject, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation of AGA or exposes the subject to an unacceptable risk by study participation. 5. Subject has normal renal, thyroid, and hepatic function as determined by the Visit 1/Screening laboratory results in the opinion of the investigator. 6. Subject is a non-smoker, defined as not having smoked or used any form of tobacco or non-tobacco products containing nicotine in more than 4 months before Visit 2/Baseline. 7. Subject is willing to maintain the same hair style, hair length, and hair color throughout the study. 8. Subject agrees to continue his other general hair care products and regimen for at least 2 weeks prior to Visit 2/Baseline, and through the entire study. 9. Subject is willing and able to apply the investigational product (IP) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study. 10. Subjects who are sexually active with a female partner and are not surgically sterile ( vasectomy performed at least 6 months prior to treatment) must agree to refrain from sperm donation for at least 90 days after administration of their last dose of IP and inform their non-pregnant female sexual partner to use a highly effective form of birth control1 as described in the informed consent form. Note: Female partner must be confirmed according to subject to be non-pregnant at Visit 1/Screening and Visit 2/Baseline or at the visit when a subject identifies a new sexual partner.
Exclusion criteria
A subject is ineligible to enter the study if he meets 1 or more of the following criteria: 1. Subject has any dermatological disorders of the scalp on the regions that are bald and thinning with the possibility of interfering with the application of the IP or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy. 2. Subject has history or active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania, or conditions/diseases other than AGA. 3. Subject has any skin pathology or condition (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns) that, in the investigator's opinion, could interfere with the evaluation of the IP or requires use of interfering topical, systemic, or surgical therapy. 4. Subject has any visible inflammatory skin disease, injury, or condition of their scalp that could compromise subject safety and/or interfere with the evaluation of local or systemic assessments performed during the study. 5. Subject has history (within 6 months of Visit 1/Screening) of severe dietary or weight changes or history of eating disorder(s), which has resulted in hair loss, in the opinion of the investigator. 6. Subject has a history of scalp reduction or notable trauma with related scarring, hair transplants, and/or hair weaves. 7. Subject has a known or suspected malignancy excluding cutaneous basal cell carcinoma or cutaneous squamous cell carcinoma not located within the treatment area. 8. Subject has a positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody. 9. Subject has any condition, which, in the investigator's opinion, would make it unsafe for the subject to participate in this study, including clinically significant abnormal laboratory, or 12-lead electrocardiogram (ECG) findings during the screening period or Visit 2/Baseline prior to dosing of the IP. 10. Subject has used any topical scalp treatments for hair growth including minoxidil, hormone therapy, anti-androgen, or other agents known to affect hair growth within 12 weeks of Visit 2/Baseline. 11. Subject has used any topical scalp over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Aminexil, Maxilene, Nioxin, Foltene) or hair growth products with saw palmetto, copper, etc. within 4 weeks of Visit 2/Baseline. 12. Subject has used any topical scalp treatments that may have ancillary effects on hair growth including, but not limited to, corticosteroids, pimecrolimus, tacrolimus, and retinoids within 4 weeks of Visit 2/Baseline. 13. Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, etc. within 6 months of Visit 2/Baseline. 14. Subject has had platelet rich plasma (PRP) procedures on the scalp at any time. 15. Subject has used systemic beta blockers, cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2/Baseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable. Stable is defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2/Baseline. 16. Subject has used systemic retinoids, isotretinoin, vitamin A intake above 10,000 IU per day, or cyclosporine therapy within 6 months of Visit 2/Baseline. 17. Subject has used finasteride (e.g., Propecia®), dutasteride, minoxidil (oral), or similar products within 6 months of Visit 2/Baseline. 18. Subject has used chemotherapy or cytotoxic agents within 12 months of Visit 2/Baseline. 19. Subject has had radiation of the scalp at any point. 20. Subject has used any other systemic therapy, which in the opinion of the investigator, may materially affect the subject's hair growth, including, but not limited to, vitamin or homeopathy supplement hair growth or hair health products or other steroid hormones (in any form), including anabolic steroids. 21. Subject is currently enrolled in an investigational drug, biologic, or device study. 22. Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days or 5 half-lives, whichever is longer, prior to Visit 2/Baseline. 23. Subject has previously been treated with the IP. 24. Subject has a history of prescription drug abuse, or illicit drug use within 6 months prior to Visit 1/Screening. 25. Subject has a history of alcohol abuse according to medical history within 6 months prior to Visit 1/Screening. 26. Subject has a positive screen for alcohol or drugs of abuse at Visit 1/Screening or Visit 2/Baseline. 27. Subject has signs or symptoms consistent with Coronavirus Disease-19 (COVID-19) at Visit 1/Screening or Visit 2/Baseline or has been diagnosed with COVID-19 within 4 weeks of Visit 1/Screening. 28. Subject has a history of sensitivity to any of the ingredients in the IP or tattoo ink. 29. Subject is known to be noncompliant or is unlikely to comply with the requirements of t the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-vellus Target Area Hair Count (TAHC) | 16 weeks | Collection of non-vellus target area hair count results at week 16 |
| Evaluation of Treatment Benefit | 16 weeks | Collection of hair growth assessment (HGA) questionnaire at week 16. Scalp hair growth will be compared from Baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Non-vellus Target Area Hair Darkness (TAHD) | 16 weeks | Non-vellus Target Area Hair Darkness (TAHD) results at week 16. Scale is a gray scale, 0(white) to 255(black) measured in a 1 cm2 area. Positive mean change is a better outcome. |
| Evaluation of Investigator's Global Assessment (IGA) Grade | 16 weeks | Collection of IGA grade at week 16. The Canfield Review application will be used. The evaluator will assess the subject's scalp hair growth using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). |
| Hair Growth Index (HGI) Questionnaire | 16 weeks | Subject's evaluation of treatment benefit via the hair growth index (HGI) questionnaire at week 16. Scalp hair growth will be compared from Baseline using the following 7-point scale: much less (-3), moderately less (-2), slightly less (-1), the same amount (0), slightly more (1), moderately more (2), and much more (3). |
| Change in Non-vellus Target Area Hair Width (TAHW) | 16 weeks | Collection of non-vellus target area hair width results at week 16 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Any Local and Systemic Adverse Events (AEs) | 20 weeks | Collection of adverse events |
| Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | 16 weeks | Collection of local skin reactions at day 1, week 2, week 4, week 8, week 12, and week 16 |
Countries
United States
Participant flow
Pre-assignment details
71 participants randomized in the study and were evaluable for safety analyses.
Participants by arm
| Arm | Count |
|---|---|
| TDM-105795 Topical Solution, 0.0025% Daily dose of 0.0025% of TDM-105795 topical solution
TDM-105795, 0.0025%: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning. | 26 |
| TDM-105795 Topical Solution, 0.02% Daily dose of 0.02% of TDM-105795 topical solution
TDM-105795, 0.02%: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning. | 23 |
| TDM-105795 Topical Vehicle Solution Daily dose of placebo for TDM-105795 topical solution
TDM-105795 topical vehicle solution: The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning. | 22 |
| Total | 71 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 6 | 4 |
| Overall Study | non-compliance | 0 | 1 | 0 |
| Overall Study | Protocol Violation | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | TDM-105795 Topical Solution, 0.0025% | TDM-105795 Topical Solution, 0.02% | TDM-105795 Topical Vehicle Solution | Total |
|---|---|---|---|---|
| Age, Continuous | 41.3 years STANDARD_DEVIATION 8.84 | 40.7 years STANDARD_DEVIATION 9.73 | 40.8 years STANDARD_DEVIATION 9.38 | 40.9 years STANDARD_DEVIATION 9.17 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 0 Participants | 3 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 23 Participants | 23 Participants | 19 Participants | 65 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 5 Participants | 5 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 24 Participants | 15 Participants | 15 Participants | 54 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 26 Participants | 23 Participants | 22 Participants | 71 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 26 | 0 / 23 | 0 / 22 |
| other Total, other adverse events | 8 / 26 | 6 / 23 | 7 / 22 |
| serious Total, serious adverse events | 0 / 26 | 0 / 23 | 0 / 22 |
Outcome results
Primary
Evaluation of Treatment Benefit
Collection of hair growth assessment (HGA) questionnaire at week 16. Scalp hair growth will be compared from Baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).
Time frame: 16 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Treatment Benefit | Slightly to moderately decreased | 4 Participants |
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Treatment Benefit | No change | 10 Participants |
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Treatment Benefit | Slightly to moderately increased | 9 Participants |
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Treatment Benefit | Missing | 3 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Treatment Benefit | Missing | 7 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Treatment Benefit | Slightly to moderately decreased | 3 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Treatment Benefit | Slightly to moderately increased | 8 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Treatment Benefit | No change | 5 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Treatment Benefit | Missing | 4 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Treatment Benefit | No change | 9 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Treatment Benefit | Slightly to moderately increased | 8 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Treatment Benefit | Slightly to moderately decreased | 1 Participants |
Primary
Non-vellus Target Area Hair Count (TAHC)
Collection of non-vellus target area hair count results at week 16
Time frame: 16 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Non-vellus Target Area Hair Count (TAHC) | 20.3 hair count | Standard Deviation 29.4 |
| TDM-105795 Topical Solution, 0.02% | Non-vellus Target Area Hair Count (TAHC) | 22.4 hair count | Standard Deviation 18.59 |
| TDM-105795 Topical Vehicle Solution | Non-vellus Target Area Hair Count (TAHC) | 14.0 hair count | Standard Deviation 17.59 |
Secondary
Change in Non-vellus Target Area Hair Darkness (TAHD)
Non-vellus Target Area Hair Darkness (TAHD) results at week 16. Scale is a gray scale, 0(white) to 255(black) measured in a 1 cm2 area. Positive mean change is a better outcome.
Time frame: 16 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Change in Non-vellus Target Area Hair Darkness (TAHD) | 4.6 score on a scale | Standard Deviation 12.27 |
| TDM-105795 Topical Solution, 0.02% | Change in Non-vellus Target Area Hair Darkness (TAHD) | 3.2 score on a scale | Standard Deviation 15.52 |
| TDM-105795 Topical Vehicle Solution | Change in Non-vellus Target Area Hair Darkness (TAHD) | -3.6 score on a scale | Standard Deviation 14.33 |
Secondary
Change in Non-vellus Target Area Hair Width (TAHW)
Collection of non-vellus target area hair width results at week 16
Time frame: 16 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Change in Non-vellus Target Area Hair Width (TAHW) | -1.27 microns | Standard Deviation 2.3 |
| TDM-105795 Topical Solution, 0.02% | Change in Non-vellus Target Area Hair Width (TAHW) | -2.18 microns | Standard Deviation 2 |
| TDM-105795 Topical Vehicle Solution | Change in Non-vellus Target Area Hair Width (TAHW) | -1.27 microns | Standard Deviation 2.2 |
Secondary
Evaluation of Investigator's Global Assessment (IGA) Grade
Collection of IGA grade at week 16. The Canfield Review application will be used. The evaluator will assess the subject's scalp hair growth using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).
Time frame: 16 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Investigator's Global Assessment (IGA) Grade | slightly to moderately increased | 13 Participants |
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Investigator's Global Assessment (IGA) Grade | No change | 9 Participants |
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Investigator's Global Assessment (IGA) Grade | slightly to moderately decreased | 1 Participants |
| TDM-105795 Topical Solution, 0.0025% | Evaluation of Investigator's Global Assessment (IGA) Grade | Missing | 3 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Investigator's Global Assessment (IGA) Grade | No change | 5 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Investigator's Global Assessment (IGA) Grade | slightly to moderately decreased | 3 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Investigator's Global Assessment (IGA) Grade | Missing | 7 Participants |
| TDM-105795 Topical Solution, 0.02% | Evaluation of Investigator's Global Assessment (IGA) Grade | slightly to moderately increased | 8 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Investigator's Global Assessment (IGA) Grade | slightly to moderately decreased | 0 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Investigator's Global Assessment (IGA) Grade | Missing | 4 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Investigator's Global Assessment (IGA) Grade | slightly to moderately increased | 6 Participants |
| TDM-105795 Topical Vehicle Solution | Evaluation of Investigator's Global Assessment (IGA) Grade | No change | 12 Participants |
Secondary
Hair Growth Index (HGI) Questionnaire
Subject's evaluation of treatment benefit via the hair growth index (HGI) questionnaire at week 16. Scalp hair growth will be compared from Baseline using the following 7-point scale: much less (-3), moderately less (-2), slightly less (-1), the same amount (0), slightly more (1), moderately more (2), and much more (3).
Time frame: 16 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Hair Growth Index (HGI) Questionnaire | Slightly to moderately less scalp | 8 Participants |
| TDM-105795 Topical Solution, 0.0025% | Hair Growth Index (HGI) Questionnaire | Missing | 3 Participants |
| TDM-105795 Topical Solution, 0.0025% | Hair Growth Index (HGI) Questionnaire | Same amount | 10 Participants |
| TDM-105795 Topical Solution, 0.0025% | Hair Growth Index (HGI) Questionnaire | Slightly to moderately more scalp | 5 Participants |
| TDM-105795 Topical Solution, 0.02% | Hair Growth Index (HGI) Questionnaire | Same amount | 4 Participants |
| TDM-105795 Topical Solution, 0.02% | Hair Growth Index (HGI) Questionnaire | Slightly to moderately more scalp | 6 Participants |
| TDM-105795 Topical Solution, 0.02% | Hair Growth Index (HGI) Questionnaire | Missing | 7 Participants |
| TDM-105795 Topical Solution, 0.02% | Hair Growth Index (HGI) Questionnaire | Slightly to moderately less scalp | 6 Participants |
| TDM-105795 Topical Vehicle Solution | Hair Growth Index (HGI) Questionnaire | Missing | 4 Participants |
| TDM-105795 Topical Vehicle Solution | Hair Growth Index (HGI) Questionnaire | Slightly to moderately less scalp | 7 Participants |
| TDM-105795 Topical Vehicle Solution | Hair Growth Index (HGI) Questionnaire | Same amount | 8 Participants |
| TDM-105795 Topical Vehicle Solution | Hair Growth Index (HGI) Questionnaire | Slightly to moderately more scalp | 3 Participants |
Other Pre-specified
Number of Participants With Any Local and Systemic Adverse Events (AEs)
Collection of adverse events
Time frame: 20 weeks
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any treatment related TEAE | 1 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any TEAE | 8 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any serious TEAE | 0 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any treatment related TEAE | 5 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any TEAE | 6 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any serious TEAE | 0 participants |
| TDM-105795 Topical Vehicle Solution | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any TEAE | 7 participants |
| TDM-105795 Topical Vehicle Solution | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any serious TEAE | 0 participants |
| TDM-105795 Topical Vehicle Solution | Number of Participants With Any Local and Systemic Adverse Events (AEs) | Subjects with any treatment related TEAE | 1 participants |
Other Pre-specified
Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs)
Collection of local skin reactions at day 1, week 2, week 4, week 8, week 12, and week 16
Time frame: 16 weeks
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TDM-105795 Topical Solution, 0.0025% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Erythema | 10 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Edema | 3 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Erosion | 1 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Scaling | 1 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Pruritus | 1 participants |
| TDM-105795 Topical Solution, 0.0025% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Burning/Stingling | 3 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Burning/Stingling | 3 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Erythema | 10 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Scaling | 4 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Pruritus | 5 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Edema | 1 participants |
| TDM-105795 Topical Solution, 0.02% | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Erosion | 1 participants |
| TDM-105795 Topical Vehicle Solution | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Edema | 2 participants |
| TDM-105795 Topical Vehicle Solution | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Erosion | 0 participants |
| TDM-105795 Topical Vehicle Solution | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Burning/Stingling | 0 participants |
| TDM-105795 Topical Vehicle Solution | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Scaling | 0 participants |
| TDM-105795 Topical Vehicle Solution | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Erythema | 2 participants |
| TDM-105795 Topical Vehicle Solution | Number of Subjects With Presence (and Severity) of Local Skin Reactions (LSRs) | Pruritus | 2 participants |